In a systematic review and meta-analysis of trials of non-vitamin K oral anticoagulants vs. single antiplatelet therapy, ...
Eligible patients were randomly assigned in a 1:1:1 ratio to receive subcutaneous injection of abelacimab at a dose of 150 mg or 90 mg once monthly or oral rivaroxaban at a dose of 20 mg once ...
The ROCKET AF trial compared rivaroxaban with dose-adjusted warfarin in patients with nonvalvular AF and a prior history of stroke or at least two other additional risk factors for stroke.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback